Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.83
(
1.17%
)
Bitcoin
71,138.88
(
-0.14%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 163702

Wednesday, 07/17/2013 11:12:28 AM

Wednesday, July 17, 2013 11:12:28 AM

Post# of 257257
(ENTA)—NVS’ 2Q13 PR* (p24) says the partial clinical hold on DEB025 has been “revised” and a DDI study has been started. The revision was presumably the FDA’s permission to conduct the DDI study, and I’m guessing that the second drug in the DDI study is ENTA’s EDP-239. (ENTA is +3% today.)

*http://www.novartis.com/cs/www.novartis.com-v4/downloads/investors/financial-results/quarterly-results/2013-07-interim-financial-report-en.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today